Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Organon
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Organon: ‘Those $4bn-$5bn Biologics – That’s A Nice Place To Play In Biosimilars’
Joe Azzinaro, Organon’s global commercial leader for biosimilars, sat down to talk with Generics Bulletin about its commercialization expertise and investments for the future.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends
From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.
Organon: Adalimumab Sales Won’t Surpass $100m In 2023, Despite US Launch
Organon has provided a relatively clear guide for how its planned launch of a US biosimilar to AbbVie’s Humira in July will impact its top line in 2023, with further detail on the coming years.
- Other Names / Subsidiaries
- Alydia Health
- Forendo Pharma Oy
- Organon NV
- Organon & Co.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.